
Sangeeta Ray, PhD
- Johns Hopkins School of Medicine Faculty
Languages
- English
Gender
FemaleAbout Sangeeta Ray
Primary Academic Title
Associate Professor of Radiology and Radiological Science
Background
Dr. Sangeeta Ray is an Associate Professor of Radiology and Radiological Science at Johns Hopkins, School of Medicine. Dr. Ray has been working in the field of developing new agents for the noninvasive molecular imaging and therapy over the last 15 years. Dr. Ray has pioneered the development of radiometal-labeled low-molecular-weight imaging agents for SPECT and PET targeting prostate-specific membrane antigen (PSMA), an important molecular target for advanced metastatic castration-resistant prostate cancer and many solid tumor neovasculature. She has been also involved in developing PSMA-based agents for MR, optical, Raman and photoacoustic imaging. The current focus of her research lab is in the development of targeted radionuclide therapy for prostate cancer and other solid tumor malignancies.
Recent News Articles and Media Coverage
2015, SNM Scientific Press release on PSMA-based MR Imaging abstract at SNM annual meeting at Baltimore, MD.
2015, “Dr. and Mrs. Peter S. Bing Scholar”, Patrick C. Walsh Prostate Cancer Research Fund.
Additional Academic Titles
Associate Professor of Oncology
Contact for Research Inquiries
1550 Orleans Street
Russell H. Morgan Department of Radiology and Radiological Sciences
Baltimore, MD 21287
Research Summary
The long-term research focus of my laboratory is to develop new imaging and therapeutic agents and nanomaterials that could contribute immensely to detection, treatment, and prevention of cancer and related diseases. Along that direction, we will continue to develop necessary chemistry and bioconjugate techniques for important cellular and molecular targets for clinical translation to improve patient-specific diagnosis and treatment option. In addition to radiopharmaceutical based SPECT and PET imaging agents, our research projects are directed to develop contrast agents for MR, fluorescence, CT and photoacoustic imaging modalities. Recent projects are also directed to develop radiotheranostics for targeted radionuclide therapy of advanced metastatic cancers.
Since 2006 my research work has been focused on developing new imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA). We have generated extensive structure-activity relationships in that regard and has contributed to several important firsts in this area, namely the design rules and synthesis of the 1st radiometallated (2008), 1st successful in vivo optical (2009) and the 1st Gallium-68-labeled (2010), the 1st dual modality SPECT-optical (2011), the 1st gadolinium magnetic resonance imaging (MR) (2015) and the 1st Chemical-Exchange Saturation Transfer (CEST) MR (2018) PSMA-targeted probes. Our Ga-68/Lu-177-labeled theranostic agent is currently undergoing multi-center phase 1 trials sponsored by Advanced Accelerator Applications/Novartis.
Selected Publications
Banerjee SR*, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs R, Pomper MG. Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 2019 (online)
Banerjee SR*, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess AP, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2019 (online)
Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox J, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed 2011; 50:9167-9170
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG. Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-5341
Patents
- Theranostic targeted nanoplexes which carry Multimodality imaging reporters together with target enzyme inhibitors, such as siRNAs and target prodrug enzymes, and their use in disease diagnosis and treatment.,
Pomper MG, Bhujwalla Z, Chen Z, Li Cong, Nimmagadda S, Penet M-F; Ray, S.
US2014/0178399A1, WO 2012135592 A2 20121004, 1/1/14 - Salicylic Acid-based Polymeric CEST Contrast agents for molecular imaging of prostate-specific membrane antigen.,
Yang X, Song X, Ray S, Pomper MG, McMahon M.
C13062, 1/1/15 - Salicylic acid, salicylic acid analogs and anthranilic acid derivatives for MRI contrast.,
Yang X, Song X, Ray S, Pomper MG, McMahon M.
WO 2014182538 A1 20141113., 1/1/14 - PSMA-targeting compounds and uses thereof. United States Patent US2015/010438A,
Pomper MG, Mease RC.; Ray S, Chen Y.
WO 2010108125 A2 20100923, 1/1/15 - PSMA-targeted nanoparticles for therapy of prostate cancer.,
Chandran SS, Ray S, Denmeade SR, Pomper MG, Mease RC.
US2011/02006779, 1/1/09 - PSMA targeted reversed carbamates and methods of use thereof.,
Pomper MG, Mease RC, Ray S,Chen Y, Yang X, Attardo, Georgio.
WO 2016065145 A2 20160428., 1/1/16 - Prostate-specific Membrane Antigen Targeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging of Prostate Cancer.,
Barman I, Li M, Ray S, Pomper MG.
JHU C13637, 1/1/15 - Prostate-specific membrane antigen targeted high-affinity agents for endo radiotherapy of prostate cancer.,
Pomper MG, Ray S.
JHU C14083 - Preparation of metal or radiometal-labeled urea- and carbamate-based PSMA inhibitors for PSMA-targeted imaging and radiotherapy.,
Ray S, Pomper MG, Meade TJ, Mease RC, Chen Y, Yang X.
WO 2015171792 A1 20151112, 1/1/15 - Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX (second generation),
Yang X, Minn I, Ray S, Rowe S, Gorin M, , Mease R, Allaf M, Pomper MG.
JHU C14017, 1/1/16 - New scaffolds and multifunctional intermediates for imaging psma and cancer therapy.,
Pomper MG, Mease RC, Ray S, Chen Y, Yang X.
WO 2016065142 A2 20160428., 1/1/16 - New homomultivalentevd heteromultivalent inhibitors of prostate specific membrane antigen (PSMA),
Pomper MG, Mease RC.; Ray S, Shallal, H.
WO 2013082338 A1 20130606, 1/1/13 - Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents,
Pomper MG, Ray S, Mease RC, Foss C.
9,044,468, WO2009/002529., 1/1/08 - Azole heterocycles for MRI contrast and pH sensing.,
Yang X, Song X, Ray S, Pomper MG, McMahon M.
WO 2014186737 A1 20141120, 1/1/14
Honors
- BriteStar Award, JHU Radiology, 1/1/19
- Roger Tsien Award Finalist, World Molecular Imaging Congress, 1/1/19
- Career Development Award, Patrick Walsh Research foundation, 5/1/15
- Dr. and Mrs. Peter S. Bing Scholar, Patrick C. Walsh Prostate Cancer Research Fund, 1/1/15
- Travel stipend for the abstract "Gd-Based Magnetic Resonance Probes for Imaging Prostate Specific Membrane Antigen (PSMA), WMIC, 1/1/13
- Career Development Award, NIH NCI, 7/1/11
- Berson-Yalow Award, Society of Nuclear Medicine, 6/6/11
Lectures & Presentations
- Design and synthesis of radiometal-based imaging agents for prostate-specific membrane antigen (PSMA), Presentation, Chemistry Club, Brain Science Institute, Johns Hopkins University, Baltimore, MD, 1/8/13
- Design and synthesis of radiopharmaceuticals for SPECT Imaging. In vivo preclinical imaging: An introductory workshop, Workshop, Society of Nuclear Medicine, Johns Hopkins University, Baltimore, MD, 3/12/12
- Design and synthesis of radiopharmaceuticals for SPECT imaging. In vivo preclinical imaging: An introductory workshop, (Session Chair),, Workshop, Society of Nuclear Medicine, Baltimore, MD, 3/11/14
- Gd-Based MR Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen, Presentation, 62nd SNMMI Annual Meeting, SNMMI, Baltimore, MD, 6/8/15
- Low-molecular weight radiolabeled theranostic agents for metastatic castration- resistant prostate cancer, Presentation, 11th Annual Johns Hopkins Prostate Research Day, Johns Hopkins University, Baltimore, MD, 10/18/16
- Metal-based prostate-specific membrane antigen (PSMA) inhibitors and their potential for cancer diagnosis and therapy., Presentation, ICMIC Seminar Series, Johns Hopkins University, Baltimore, MD, 9/30/09
- Prostate-specific membrane antigen targeted nanoparticles for imaging and therapy of prostate cancer, Presentation, National Science and Technology Innovation (Cancer Nanotechnology) Symposium, TechConnect World 2014, Gaylord Convention Center, Gaylord, MD, 6/16/14
- Prostate-specific membrane antigen-based compounds for imaging and therapy of prostate cancer, Presentation, ICMIC Seminar Series, Johns Hopkins University, Baltimore, MD, 10/11/12
- PSMA Targeted Gd-Based MR/PET Contrast Agents for Imaging Prostate Cancer, Presentation, NCI Alliance for Nanotechnology in Cancer, NCI Alliance for Nanotechnology in Cancer, Houston, TX, 10/17/12
- Radiometal-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer, Presentation, ICMIC Seminar Series, Johns Hopkins University, Baltimore, MD, 10/16/11
- Synthesis and evaluation of gadolinium-based contrast agents for MR imaging of prostate-specific membrane antigen (PSMA), Presentation, ICMIC Seminar Series, 4/30/14
Memberships
- Member of the SNMMI WINM Program Working Group
- American Chemical Society
- Society of Nuclear Medicine
- World Molecular Imaging Society
- American Association of Cancer Research
- Society of Radiopharmaceutical Science
Professional Activities
- Abstract reviewer, World Molecular Imaging Congress (WMIC), 1/1/19
- Advisor, Precision Molecular Inc. (A JHU startup pharmaceutical company), 1/1/19
- American Journal of Nuclear Medicine and Molecular Imaging, Associate Editorial Board, 1/1/19
- Grant review, Prostate Cancer UK
- Grant review, Tobacco-Related Disease Research Program, University of California
- Grant Review, JHU radiology internal funding mechanism
- Journal Review, Journal of Nuclear Medicine, 1/1/19
- Journal Review, Journal of Medicinal Chemistry, 1/1/19
- Journal Review, Nuclear Medicine and Biology, 1/1/19
- Journal Review, Molecular Imaging, 1/1/19
- Journal Review, The Prostate, 1/1/19
- Journal Review, Applied Radiation and Isotopes, 1/1/19
- Journal Review, International Journal of Molecular Imaging, 1/1/19
- Journal Review, Molecular Pharmaceutics, 1/1/19
- Journal Review, Journal of Radioanalytical and Nuclear Chemistry, 1/1/19
- Journal Review, Bioconjugate Chemistry, 1/1/19
- Journal Review, Molecules, 1/1/19
- Journal Review, Biomaterials, 1/1/19
- Journal Review, Journal of Labelled Compounds and Radiopharmaceuticals, 1/1/19
- Journal Review, ChemMedChem, 1/1/19
- Journal Review, Cancer Biotherapy and Radiopharmaceuticals, 1/1/19
- World Molecular Imaging Congress (WMIC), Abstract reviewer, 1/1/12